About Neuromyelitis optica spectrum disorder with anti-MOG antibodies
Neuromyelitis optica spectrum disorder with anti-MOG antibodies is a rare disease catalogued by Orphanet (ORPHA:592856). Search below for active recruiting clinical trials from ClinicalTrials.gov, or visit the Orphanet expert page for specialist centres, natural history studies, and patient registries worldwide.
Clinical Trial Eligibility Tips
What to know before applying to Neuromyelitis optica spectrum disorder with anti-MOG antibodies trials.
Search ClinicalTrials.gov for "Neuromyelitis optica spectrum disorder with anti-MOG antibodies" or Orphanet code ORPHA:592856 to find disease-specific recruiting studies.
Ask your specialist to refer you to an Orphanet-accredited Centre of Expertise for this condition.
Natural history studies and patient registries often open enrolment before drug trials — contact the Orphanet patient community first.
Patient Resources
Find recruiting Neuromyelitis optica spectrum disorder with anti-MOG antibodies trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Neuromyelitis optica spectrum disorder with anti-MOG antibodies. Updated daily.